PTSD

Mental health issues are something most of us encounter, whether with ourselves or loved ones. Veterans struggle with mental health issues at a disproportionate rate compared to the general population, with many experiencing symptoms of post-traumatic stress disorder (PTSD) and depression....

atai Life Sciences (NASDAQ: ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds. What Happened: The clinical-stage biotechnology company focused on discovering and developing mental health treatments using psychedelic therapy said...

Nick Watchorn had suffered for most of his adult life from severe post-traumatic stress disorder (PTSD) before he sought psychedelic treatments to deal with his chronic condition. He credits those psychoactive sessions, and particularly the work he did afterwards in a process known as integration...

Ketamine One, a Canada-based health and wellness company focused on treatments for mental health, is teaming up with Cognetivity Neurosciences (OTCMKTS: CGNSF) for a collaborative study on treatments for PTSD and depression, the companies announced in a press release on Thursday.  Ketamine One...

After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program will consist of two separate studies to evaluate NYX-783 at two dose levels: 50 mg (...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are gaining momentum following a Thursday morning announcement from the company.  What Happened Tonix, a biopharma company developing treatments for serious neuropsychiatric and central nervous system conditions, said it plans to...